# Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.

> **NCT04166656** · PHASE3 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 84 (estimated)

## Conditions studied

- Splenectomy

## Interventions

- **BIOLOGICAL:** Trumenba®
- **BIOLOGICAL:** Bexsero®

## Key facts

- **NCT ID:** NCT04166656
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-15
- **Primary completion:** 2028-09
- **Final completion:** 2028-10
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2025-11-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04166656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04166656, "Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04166656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*